Related Experiment Video
Updated: May 15, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors]
C Hernández-Marqués1, A Lassaletta-Atienza, A Ruiz Hernández
1Servicio de Hemato-Oncología Pediátrica, Hospital Infantil Universitario Niño Jesús, Madrid, Spain.
Anales De Pediatria (Barcelona, Spain : 2003)
|January 22, 2013
Summary
The combination of irinotecan and temozolomide shows promise for treating refractory or relapsed pediatric solid tumors. This treatment is well-tolerated and effective, offering a new option for young cancer patients.
Area of Science:
- Pediatric Oncology
- Medical Chemotherapy
Background:
- Refractory or relapsed pediatric solid tumors have a poor prognosis with no standard treatment.
- Irinotecan and temozolomide combination is effective in adult solid tumors and some pediatric cancers.
Purpose of the Study:
- To evaluate the efficacy and tolerability of irinotecan and temozolomide in pediatric patients with refractory or relapsed solid tumors.
Main Methods:
- Retrospective study of 32 pediatric patients treated with irinotecan and temozolomide.
- Analysis of clinical characteristics, treatment, toxicity, and outcomes.
Main Results:
- 10 out of 30 evaluable patients (33%) showed a positive response (2 complete, 8 partial remission).
- Disease stabilization occurred in 8 patients (27%); 94% achieved response within four cycles.
- Toxicity was observed in 28% of cycles (8% grade iii-iv), with diarrhea being the most common.
Conclusions:
- Irinotecan and temozolomide combination is well-tolerated in pediatric patients.
- The combination demonstrates activity against refractory or relapsed pediatric solid tumors.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...